A cette occasion, trois entreprises membres de Lyonbiopôle interviendront : PX'Therapeutics, ERYtech Pharma et Metabloys.

 

Ce workshop scientifique se tiendra le Mardi 27 Octobre 2009 dans les locaux de Genzyme à Cambridge (Massachusetts). Il est organisé en partenariat avec la Chambre du commerce franco-américaine, le bureau Science et Technologie de l'Ambassade de France aux Etats-Unis et Hubtech 21 Europe-USA. A noter l'intervention de personnalités du Tufts University, de Genzyme et Novartis

Programme

 

Tuesday, October 27^th 2009, at the Genzyme Center, 5.30 to 7.30 pm

The Roscoe Brady lecture Hall, 500 Kendall Street, Cambridge, MA 02142

 

 

5.30 - 7.00 pm:  Presentations

 

Dan Snell, Ph.D., Associate Director, Antibody Therapeutics, Genzyme, Cambridge, UK

Towards the next generation of biopharmaceuticals.

 

Maud Bouvier, Ph.D., Business Development Manager, ERYtech Pharma, Lyon, France

Protein immune tolerance induction: an Innovative solution

 

Janice Reichert, Ph.D., Senior Research Fellow, Tufts CSDD, and Editor-in-Chief of mAbs, Tufts University, publisher of mAbs is Landes Bioscience, Boston, USA

Monoclonal antibodies in the pharma landscape:  new directions and challenges

 

Gabriel Baverel Ph.D., Metabolys, CEO, Lyon, France

Cellular metabolomics : a precious tool to predict the safety of drug candidates and biologics

 

Antu Dey, Ph.D., Investigator, Protein Biochemistry, Vaccines & Diagnostics Division, Novartis, Cambridge, USA

Developing monoclonal antibodies against viral targets & challenges therewith

 

Tristan Rousselle, Ph.D., CEO & co-Founder, PX Therapeutics, Grenoble France

Main issues for the development of biologics, from bench to GMP production

 

7. 00 - 7.30 pm:  Cocktail

 

Télécharger le programme et la fiche d'inscription

Inscription avant le 23 octobre 2009